EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Hybrid immunity to SARS‐CoV ‐2 in patients with chronic lymphocytic leukemia

Sibylle C Mellinghoff iD, Sandra Robrecht iD, Rosanne Sprute, Leonie Mayer iD, Leonie M Weskamm iD, Christine Dahlke iD, Henning Gruell iD, Finn Teipel iD, Hans A Schlößer iD, Klara Siepmann, Martin Thelen iD, Anna-Maria Fink iD und 8 weitere

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14170 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Sibylle C Mellinghoff und 19 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldor…. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Preventing severe COVID‐19 remains a priority globally, particularly in the immunocompromised population. As shown in healthy individuals, immunity against SARS‐CoV‐2 can be yielded by previous infection, vaccination, or both (hybrid immunity). The objective of this observation study was to investigate hybrid immunity in patients with chronic lymphocytic leukemia (CLL). Methods/Results Blood samples of six patients with CLL were collected 55 days after fourth COVID‐19 vaccination. All patients had a SARS‐CoV‐2 infection within 12 months before the second booster (fourth vaccination). SARS‐CoV‐2 spike receptor binding domain (RBD)‐specific IgG antibodies were detectable in 6/6 (100.0%) CLL patients after four compared to 4/6 (66.7%) after three vaccinations. The median number of SARS‐CoV‐2 spike‐specific T cells after repeated booster vaccination plus infection was 166 spot‐forming cells (SFC) per million peripheral blood mononuclear cells. Overall, 5/5 (100%) studied patients showed a detectable increase in T cell activity.

Conclusion

Our data reveal an increase of cellular and humoral immune response in CLL patients after fourth COVID‐19 vaccination combined with SARS‐CoV‐2 infection, even in those undergoing B cell‐depleting treatment. Patients with prior vaccination failure now show a specific IgG response. Future research should explore the duration and effectiveness of hybrid immunity considering various factors like past infection and vaccination rates, types and numbers of doses, and emerging variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellCOVID-19HumansSARS-CoV-2COVID-19 VaccinesLeukocytes, MononuclearImmunoglobulin GPostoperative ComplicationsVaccinationAdaptive ImmunityAntibodies, Viral

Stichwörter der Autor:innen

CLLCOVID vaccinationhybrid immunityvaccine‐induced immunity

Substanzen

COVID-19 VaccinesImmunoglobulin GAntibodies, Viral

Autor:innen und Institutionen

  • Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Univer…
  • German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
  • Faculty of Medicine and University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Ger…
  • Department of Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
  • Institute for Infection Research and Vaccine Development (IIRVD), University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
  • German Centre for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.

ORCID-Profile: Sibylle C Mellinghoff, Sandra Robrecht, Leonie Mayer, Leonie M Weskamm, Christine Dahlke, Henning Gruell, Finn Teipel, Hans A Schlößer, Martin Thelen, Anna-Maria Fink, Marylyn M Addo, Androniki Kolovou, Oliver A Cornely, Barbara Eichhorst, Michael Hallek, Petra Langerbeins

Zitieren

APA

Mellinghoff, S. C., Robrecht, S., Sprute, R., Mayer, L., Weskamm, L. M., Dahlke, C., Gruell, H., Teipel, F., Schlößer, H. A., Siepmann, K., Thelen, M., Fink, A. M., Fischer, K., Klein, F., Addo, M. M., Kolovou, A., Cornely, O. A., Eichhorst, B., Hallek, M., & Langerbeins, P. (2024). Hybrid immunity to SARS‐CoV ‐2 in patients with chronic lymphocytic leukemia. European Journal of Haematology. https://doi.org/10.1111/ejh.14170

Vancouver

Mellinghoff SC, Robrecht S, Sprute R, Mayer L, Weskamm LM, Dahlke C, et al. Hybrid immunity to SARS‐CoV ‐2 in patients with chronic lymphocytic leukemia. European Journal of Haematology. 2024. doi:10.1111/ejh.14170

BibTeX
@article{Mellinghoff2024,
  author = {Mellinghoff, Sibylle C and Robrecht, Sandra and Sprute, Rosanne and Mayer, Leonie and Weskamm, Leonie M and Dahlke, Christine and Gruell, Henning and Teipel, Finn and Schlößer, Hans A and Siepmann, Klara and Thelen, Martin and Fink, Anna-Maria and Fischer, Kirsten and Klein, Florian and Addo, Marylyn M and Kolovou, Androniki and Cornely, Oliver A and Eichhorst, Barbara and Hallek, Michael and Langerbeins, Petra},
  title = {Hybrid immunity to SARS‐CoV ‐2 in patients with chronic lymphocytic leukemia},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14170}
}
Kostenlos starten →